Sirák Igor, Petera Jirí, Zoul Zdenek
Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Oncology and Radiotherapy, Czech Republic.
Acta Medica (Hradec Kralove). 2008;51(2):95-9. doi: 10.14712/18059694.2017.9.
The objective of this study was to evaluate the influence of cisplatin dose upon 3-year overall and disease-free survival rate of patients with advanced cervical cancer treated with concurrent chemoradiotherapy with weekly cisplatin. Seventy-three patients with stage IIB-IVA cervical carcinoma were treated with pelvic (or pelvic + paraaortic) external-beam radiotherapy, high-dose rate brachytherapy and concomitant chemotherapy with weekly cisplatin of 40 mg/m2 in the time period form January 2000 to December 2006 at our department. The 3-year overall survival and disease-free suvival rates were evaluated with regard to the number of cisplatin cycles applied during the external radiotherapy. Only twenty-eight patients received the intended five doses of chemotherapy. The most frequent cause of chemotherapy delay was the acute hematological toxicity with leukopenia. The 3-year overall survival was 71 % and the 3-year disease-free survival was 61 %. Survival analyses didn't prove a statistically significant influence of cisplatin dose upon 3-year survival in cervical carcinoma patients treated by exclusive chemoradiation with weekly cisplatin.
本研究的目的是评估顺铂剂量对接受每周一次顺铂同步放化疗的晚期宫颈癌患者3年总生存率和无病生存率的影响。2000年1月至2006年12月期间，在我科对73例IIB-IVA期宫颈癌患者进行了盆腔（或盆腔+腹主动脉旁）外照射放疗、高剂量率近距离放疗以及每周40mg/m²顺铂的同步化疗。根据外照射期间应用顺铂的周期数评估3年总生存率和无病生存率。只有28例患者接受了预定的5次化疗剂量。化疗延迟的最常见原因是急性血液学毒性伴白细胞减少。3年总生存率为71%，3年无病生存率为61%。生存分析未证明顺铂剂量对接受每周一次顺铂单纯放化疗的宫颈癌患者3年生存率有统计学上的显著影响。
